Thermo Fisher Scientific Inc. $TMO Shares Purchased by Carmignac Gestion

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Carmignac Gestion raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 189,172 shares of the medical research company's stock after buying an additional 33,019 shares during the period. Thermo Fisher Scientific makes up about 1.5% of Carmignac Gestion's investment portfolio, making the stock its 21st largest holding. Carmignac Gestion owned approximately 0.05% of Thermo Fisher Scientific worth $94,152,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of TMO. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after purchasing an additional 1,433,444 shares during the period. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth $532,360,000. Kovitz Investment Group Partners LLC increased its stake in shares of Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after acquiring an additional 858,193 shares during the last quarter. Finally, Farallon Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after acquiring an additional 523,800 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $488.15 on Tuesday. The firm has a market cap of $184.33 billion, a price-to-earnings ratio of 28.23, a PEG ratio of 2.61 and a beta of 0.74. The company has a 50 day moving average of $436.43 and a 200-day moving average of $458.25. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 earnings per share. The company's revenue was up 2.9% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,400 shares of company stock worth $8,345,792. Insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. HSBC reaffirmed a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Royal Bank Of Canada decreased their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.